Pharmaceuticals & Medical
Mainstream GS assists leading pharmaceutical, biotechnology and medical device companies with operating in this new era of Universal Health care. This new area is full of risks as companies evolve from a product-driven to a consumer-driven market-place. Additionally the role of government in this new era is not clearly defined. In many pharmaceutical companies research & development productivity has declined and continues to decline, patent expirations are increasing and new game-changer drugs are scarce.
As a result, Mainstream GS believes market consolidation will become a key business strategy for top line growth and cost reduction.
Mainstream GS is well positioned to assist clients with M&A integration and Process redesign to reduce costs and improve overall operational effectiveness.
Our consultants can assist your organization in addressing critical and urgent business challenges, including:
- Capital Asset Productivity
- Process Improvement
- Sales Force Effectiveness
- Merger & Acquisition Integration
- Cost reduction
- Supply Chain Effectiveness